Controlling the type 1 error rate in non-inferiority trials

Statistics in Medicine

Volumn 27, Issue 3, 2008, Pages 371-381

  Snapinn, Steven ^a   Jiang, Qi ^a  

^a AMGEN INC   (United States)

Author keywords

Assay sensitivity; Constancy; Fixed margin approach; Power; Synthesis method

Indexed keywords

ANALYTICAL ERROR; ANEMIA; ARTICLE; BLOOD TRANSFUSION; CLINICAL EFFECTIVENESS; CLINICAL RESEARCH; CONFIDENCE INTERVAL; HAZARD RATIO; METHODOLOGY; SAMPLE SIZE; SENSITIVITY AND SPECIFICITY;

BIAS (EPIDEMIOLOGY); CLINICAL TRIALS AS TOPIC; HUMANS; MODELS, STATISTICAL; UNITED STATES;

EID: 38949171665     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.3072     Document Type: Article

References (22)

1. Snapinn S, Jiang Q. Preservation of effect and the regulatory approval of new treatments on the basis of non-inferiority trials. Statistics in Medicine 2007; DOI: 10.1002/sim.3073.
2. CBER/FDA Memorandum. Summary of CBER considerations on selected aspects of active controlled trial design and analysis for the evaluation of thrombolytics in acute MI, June 1999.
3. Snapinn SM. Non-inferiority trials. Current Controlled Trials in Cardiovascular Medicine 2000; 1:19-21.
4. International Conference on Harmonisation. Guidance on choice of control group and related design and conduct issues in clinical trials (ICH E-10). International Conference on Harmonization, July 2000.
5. D'Agostino Sr RB, Massaro JM, Sullivan LM. Non-inferiority trials: design concepts and issues - the encounters of academic consultants in statistics. Statistics in Medicine 2003; 22:169-186.
6. Committee for Medicinal Products for Human Use (CHMP). Guideline on the choice of the non-inferiority margin. EMEA/CPMP/EWP/2158/99, July 27, 2005.
7. Holmgren EB. Establishing equivalence by showing that a specified percentage of the effect of the active control over placebo is maintained. Journal of Biopharmaceutical Statistics 1999; 9:651-659.
8. Hasselblad V, Kong DF. Statistical methods for comparison to placebo in active-controlled trials. Drug Information Journal 2001; 35:435-449.
9. Hung HMJ, Wang S-J, Tsong Y, Lawrence J, O'Neill RT. Some fundamental issues with non-inferiority testing in active controlled trials. Statistics in Medicine 2003; 22:213-225.
10. Rothmann M, Li N, Chen G, Chi GYH, Temple R, Tsou H-H. Design and analysis of non-inferiority mortality trials in oncology. Statistics in Medicine 2003; 22:239-264.
11. Snapinn SM. Alternatives for discounting in the analysis of noninferiority trials. Journal of Biopharmaceutical Statistics 2004; 14:263-273.
12. Jones B, Jarvis P, Lewis JA, Ebbutt AF. Trials to assess equivalence: the importance of rigorous methods. British Medical Journal 1996; 313:36-39.
13. Hauck WW, Anderson S. Some issues in the design and analysis of equivalence trials. Drug Information Journal 1999; 33:109-118.
14. Temple R, Ellenberg SS. Placebo-controlled trials and active-controlled trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Annals of Internal Medicine 2000; 133:455-463.
15. Ellenberg SS, Temple R. Placebo-controlled trials and active-controlled trials in the evaluation of new treatments. Part 2: practical issues and specific cases. Annals of Internal Medicine 2000; 133:464-470.
16. Siegel JP. Equivalence and non-inferiority trials. American Heart Journal 2000; 139:S166-S170.
17. Wang SJ, Hung HMJ, Tsong Y. Utility and pitfall of some statistical methods in active controlled clinical trials. Controlled Clinical Trials 2002; 23:15-28.
18. Wang SJ, Hung HMJ. TACT method for non-inferiority testing in active controlled trials. Statistics in Medicine 2003; 22:227-238.
19. Chan ISF. Power and sample size determination for noninferiority trials using an exact method. Journal of Biopharmaceutical Statistics 2002; 12:457-469.
20. Zhang P. A simple formula for sample size calculation in equivalence studies. Journal of Biopharmaceutical Statistics 2003; 13:529-538.
21. Jung S-H, Kang SJ, McCall LM, Blumenstein B. Sample size computation for two-sample noninferiority log-rank test. Journal of Biopharmaceutical Statistics 2005; 15:969-979.
22. Kaul S, Diamond GA. Good enough: a primer on the analysis and interpretation of noninferiority trials. Annals of Internal Medicine 2006; 145:62-69.